Journal of Health, Medicine and Nursing
ISSN 2422-8419 An International Peer-reviewed Journal
Vol.43, 2017

Treatment of Hypertensive Crisis Using Beta Blockers Vs Diuretics: Review

Munwah Salah Rushydan Alrushydan[1*](first -author) Abdulaziz Mohammed H Hammudah[2] (co-author)
Ahmed Hamza Mohammedalhadi[2] (co-author) AbdulmajeedMualla M Alotaibi[2] (co-author)
Ibrahim Abdulrahman Ibrahim Alrubayan[2] (co-author) Khalid Saud Aloufi[2] (co-author)
Alhareth Khalid Alhussain[3](co-author) HussamSaeed Alzahrani[3](co-author)
1.School of Medicine, Almaarefa Colleges
2.Faculty of Medicine, Medical University of Gdansk
3.School of Medicine, Medical University of Silesia

Abstract
Current review aiming to evaluate and the advantage and disadvantage and also to discuss the differences in use and combination therapy of beta blockers VS diuretics in the treatment of hypertensive crisis. Literature were search on topic concerning the treatment of hypertensive crisis, using biomedical databases; PubMed, and Embase, up to August, 2017. Patients with hypertensive crises could call for immediate reduction in raised high blood pressure to stop and also detain modern end-organ damage. The best scientific setup in which to attain this blood pressure control remains in the intensive care unit, with making use of titratable intravenous hypotensive agents. Beta-blocker- based therapy, numerous possible randomized trials have recorded that diuretic-based treatment is efficient in reducing morbidity and also mortality in hypertensive patients. The advantages of diuretic therapy have actually been shown to be more significant in the senior compared to in younger patients. The result of diuretics is especially articulated when it comes to decrease of the risk of stroke and also somewhat less excellent with regard to the reduction of the danger of coronary heart disease.
Keywords: Hypertension, Diuretics Therapy, Beta Blocker, Hypertensive Crisis.

Introduction

Hypertension (HTN) is a very widespread condition approximated to be located in around 26% of the grown-up populace globally [(1)]. And is projected to reach 1.56 billion by 2025 [(2)], HTN is the leading cause of death and also the 2nd leading source of lost disability-adjusted life-years worldwide [(2)].HTN stays among the significant avoidable danger variables for coronary events, stroke, cardiac arrest, peripheral vascular condition, as well as the progression of kidney disease [(3)]. Regardless of current advances in treatment as well as raised understanding among both patients as well as doctors, a large proportion of the hypertensive population remains to have suboptimal BP control, although it is enhanced when compared with previous data [(4,5)].

Drug treatment is required if lifestyle modifications cannot sufficiently bring BP to objective. First-line medications used in the treatment of high blood pressure consist of diuretics, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), beta-blockers, as well as calcium channel blockers (CCBs). Some patients will call for 2 or even more antihypertensive medications to attain their BP target [(2,4)]. In newly diagnosed patients with BP > 20/10 mm Hg above objective, antihypertensives or a combination hypertensive might be added quickly [(6)].

The goal of hypertension therapy is to decrease BP to <140/90 mm Hg; nevertheless, in patients with hypertension as well as diabetes or renal illness, the BP goal is also reduced, targeted at ≤ 130/80 mm Hg [(6)]. In particular, hypertensive emergency situations and hypertensive seriousness are typically experienced in the emergency situation division, operating room, postanaesthesia care unit, and also intensive care units [(4,5,6)]. One of the most important variables that restrict morbidity as well as mortality from these problems is prompt as well as meticulously taken into consideration therapy [(5,6)].

Current review aiming to evaluate and the advantage and disadvantage and also to discuss the differences in use and combination therapy of beta blockers VS diuretics in the treatment of hypertensive crisis.

Methodology

Literature were search on topic concerning the treatment of hypertensive crisis, using biomedical databases; PubMed, and Embase, up to August, 2017. MeSH terms were used in review search such following, “hypertension”, High Blood pressure”, “hypertensive crisis” combined with “Beta-blocker”, OR “Diuretics”. Further, references from found articles were searched manually for more relevant studies. Only English language published studies were searched.

Discussion

Use of β-blockers to deal with hypertension started in the 1960's, as these representatives were huge improvement in regards to unfavorable effects over the existing antihypertensive medications in fashion at the

time, such as ganglionic blockers, guanethidine, or methyldopa (7). Given that the introduction of more recent classes of antihypertensive medicines, such as angiotensin-converting enzyme preventions (ACEIs), angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs), β-blockers have actually been subjected to a much more rigid analysis as well as their performance is normally contrasted with these brand-new agents. The β-blockers are still favored in hypertensive patients who have struggled with myocardial infarction (MI), or various other forms of IHDs, as well as HF because of systolic dysfunction, but not in hypertensive patients without comorbidities [8,9]. Beta-blockers are generally stayed clear of in patients struggling with bronchial asthma, or with airway hyper-reactivity. Their usage as first-line therapy for hypertension initially came under criticism in the 1990's when it was shown by meta-analyses of medical tests that β-blockers did not stop coronary heart disease (CHD), or considerably reduce all-cause and cardiac mortality. Propranolol showed little advantage against stroke as well as none on coronary occasions in elderly British patients [10]. Beta-blockers were also found much less efficient in lowering systolic high blood pressure (SBP) and diastolic high blood pressure (DBP) in hypertensive patients than those treated with CCBs, aceis, as well as arbs, as well as significantly less patients proceeded their treatment with β-blockers [11].

Despite the disagreements, the majority of national guidelines still do not prohibit using β-blockers as first-line medications for the preliminary therapy of high blood pressure. The European Society of Hypertension (ESH) Task Force rejected the classification and also position of antihypertensive medicines into very first, second, or third-line medicines, as the category is not justified on sensible and also clinical basis [12]. The ESH competes that the 5 major antihypertensive drug courses, that is, CCBs, ACEIs, Diuretics, β-blockers, as well as arbs, do not differ significantly in their capability to lower BP, or offer an absolute proof of protection against overall cardio risks, such as stroke, or MI [13].

Effect of Beta-Blockers on heart rate (HR):

The meta-analysis carried out by Bangalore et al.[14]showed an inverted connection in between beta-blocker-induced heart rate decreasing as well as the decrease in the risk of future cardio events in patients with hypertension [14]. This heart rate decreasing causes a pseudo antihypertensive result; that is, the central aortic pressure comes to be less than the brachial pressure [15,16]. This phenomenon is thought to be among mechanisms underlying the reduced cardiovascular-protective impacts of beta-blockers. On the other hand, high heart rate is known as an independent threat aspect for significant cardio events. The risk seems to enhance as the heart rate starts to go beyond 70 bpm [17]. The aforementioned meta-analysis carried out by Bangalore et al. demonstrated an inverse relationship in between heart price and also cardio events in topics with heart rates under 70 bpm, as well as no study till the present day has taken a look at the relationship in between the heart rate and also the danger for cardiovascular occasions in cases obtaining beta-blocker therapy with heart prices over 70 bpm. Atenolol was utilized in more than 80% of the study subjects of the meta-analysis carried out by Bangalore et al. [14]. Therefore, no research has actually examined the association in between the reduction in heart price and also the increased risk of cardio occasions by the therapy with beta-blockers aside from atenolol. Our previous potential research study determined high heart rate as an independent risk aspect for vascular damage [18].

Infectivity of beta blockers and variation of different beta blockers:

Prichard classified beta-blockers right into three types according to their beta1-selectivity and also vasodilatory potential [19]. An added classification is hydrophilic or lipophilic beta-blockers [20,21]. Atenolol is a beta1-selective agent, as well as it has been extensively made use of as the control medicine in big randomized possible controlled trials of newer antihypertensive agents such as calcium network blockers as well as renin-angiotensin (RA) system blockers. (**Table 1**) sums up the possible reasons that beta-blockers are thought about to be reasonably ineffective for the avoidance of cardiovascular events [22,23].

Table 1: Plausible reasons for beta-blockers being relatively ineffective for the prevention of cardiovascular events.

Less effective lowering of the blood pressure
Visit-to-visit blood pressure instability
Less effective lowering of the central blood pressure
Less effective regression of the left ventricular hypertrophy
Unfavorable metabolic effects
Less effective vascular protection
Reduced drug compliance

In the Anglo-Scandinavian Cardiac Results Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) research, high blood pressure worths were lower in those assigned to the calcium channel blocker-based program as

compared to those alloted to the beta-blocker-based program throughout the trial period [24]. Recently, Webb et al. reported a meta-analysis in which they explained visit-to-visit high blood pressure instability in patients obtaining beta-blocker therapy [25], and that this instability was related to an increased threat of stroke [26]. Atenolol was utilized in the ASCOT-BPLA study, and also not just the analysis conducted by Webb et al. [25] but additionally that carried out by Rothwell et al. [26] entailed using atenolol. Some studies demonstrated that once-daily atenolol does not supply sufficient high blood pressure control throughout the night-time and early morning durations as a result of its pharmacokinetic profile as well as half-life [27,28]. These medicine profiles of atenolol could be the reason for its reasonably weak blood pressure-lowering effect and the blood pressure instability. On the other hand, metoprolol or bisoprolol have been shown to be a lot more effective in maintaining Early and also 24-hour morning BP reductions as compared with atenolol [29,30].

In the arterial tree, the arteries branch and also taper as they reach peripheral websites, connected with the boost of the arterial resistance. Reflected pulse wave (from the periphery to the heart) happens at sites of sudden increase of the arterial resistance, such as at websites of arterial branching. Communication in between the event pulse wave (from the heart to the perimeter) and also mirrored pulse wave (from the periphery to the central region) is observed in the arterial tree (**Figure 1**); therefore, the high blood pressure worths vary in between main as well as peripheral sites of the arterial tree [31]. Central (aortic and carotid) high blood pressure is pathophysiologically a lot more appropriate than the outer pressure in the pathogenesis of cardiovascular disease [32]. Enhancement index (AI), a marker of the communication of case stress wave and also mirrored pressure wave, was significantly and inversely related to heart rate due to a change in the loved one timing of the mirrored pressure wave [33]. Beta-blockers decrease the heart rate as well as reduce AI, which minimizes their effectiveness in reducing the central blood pressure as compared to other antihypertensive agents [34]. In their meta-analysis, Fagard et al. reported that beta-blockers put in a reasonably weak impact in causing regression of the left ventricular mass [35]. In Fagard et al.[36] testimonial, atenolol was utilized in about 70% of the research study topics prescribed beta-blockers, and also no research involving making use of vasodilatory beta-blockers was consisted of. Recently, the benefits of nebivolol, a vasodilatory beta-blocker, over traditional β-blockers in decreasing the central high blood pressure and also causing regression of the left ventricular mass have been reported [36]. Compared to atenolol, nebivolol applies a much more positive result on 24-hour high blood pressure profile [37]. Nebivolol and also telmisartan, an angiotensin II receptor blocker, reduced the left ventricular mass to a comparable degree [38].



Fig.1: Schema of propagation of the incident pulse wave, reflected pulse wave

Effect of diuretic treatment on heart failure (HF):

Thiazide diuretic is very effective instopping the development of cardiac arrest (HF) in hypertensive patients. In a huge meta-analysis that consisted of 18 lasting placebo-controlled randomized tests, high-dose diuretic therapy lowered the danger of HF by 83% and low-dose diuretic minimized the danger of HF by 42% [39]. In the Hypertension in the Very Elderly Trial (HYVET), indapamide minimized the rate of HF by 64% in very elderly patients with hypertension [40]. In INSIGHT, diuretic was much more effective compared to nifedipine in protecting against nonfatal HF [41]. In the ALLHAT study, chlorthalidone transcended to doxazosin, lisinopril, and amlodipine in preventing HF [42,43]. The information were confirmed after an extensive analysis of all hospitalized HF events [44]. In a subanalysis of ALLHAT, chlorthalidone was superior to the other representatives in protecting against HF in participants with the metabolic disorder as well as in patients with diabetic issues [45]. One of the arguments against the searchings for of the ALLHAT research was that the attained BP in the chlorthalidone arm was lower than the achieved BP in the other therapy arms. Nevertheless, evaluations utilizing achieved BP degrees as time-dependent covariates in a Cox proportional danger regression version showed that after modification for BP, the distinctions in risk of stroke as well as HF in between treatment arms remained statistically substantial [45]. In the ACCOMPLISH trail, the mix of benazepril with hydrochlorothiazide was as efficient as the combination of benazepril with amlodipine in stopping HF [46]. Hence, it is clear that diuretic is really effective and also may transcend to other agents in stopping new-onset HF in hypertensive patients.

Hypertension management by diuretics in elderly

Hypertension is much a lot more common in the senior, and in this age-- team, isolated systolic hypertension is specifically usual. A number of placebo-controlled research studies revealed the efficiency of diuretics in decreasing Curriculum Vitae morbidity and mortality in the elderly [40]. In the Systolic Hypertension in the Elderly Program (SHEP) [47], chlorthalidone decreased in elderly patients with isolated systolic hypertension the price of total stroke by 36%, the price of major Curriculum Vitae occasions by 32%, as well as the rate of all-cause mortality by 13%. We have shown in a meta-analysis that in the senior, diuretics are a lot more efficient than β-blockers in decreasing BP [48]. Only diuretics minimized the threat of coronary heart condition and all-cause mortality [48]. The ALLHAT research study, which showed superiority of diuretics over other antihypertensive agents in some second end points (see over), was not specified as a research of the elderly, but 57.5% of the participants were age ≥ 65 years; as a result, this research is thought about a research in the senior [42,43]. The only exception was the ANBP2 research, in which treatment with an ACE prevention in older subjects, especially males, caused better results compared to treatment with diuretic agents, in spite of similar decreases of BP [49]. It is significant that the style of the ANBP2 research study was much less extensive compared to various other researches, considering that it was a potential, randomized, open-label, blinded-endpoint (PROBE) research study that is open to bias. In the ANBP2 study, only 83% of the participants obtained their appointed treatment, only 58% of individuals were arbitrarily assigned to an ACE prevention, and 62% of those appointed to a diuretic were still getting designated treatment at the end of the research [49]. In the current HYVET [40], indapamide lowered the price of stroke, coronary cardiovascular disease, HF, as well as all-cause mortality.

Benefits of diuretics in management of HTN:

Several studies showed that diuretics stop the advancement of osteoporosis and also decrease the risk of hip fractures [50,51]. In a randomized double-blind 2-year test, Reid et al. [51] revealed that hydrochlorothiazide reduced cortical bone loss in normal postmenopausal ladies. Schoofs et al. [50] received a possible population-based accomplice study that thiazide safeguards against hip fractures and that this safety effect disappears within 4 months after usage is ceased. Thus, in addition to their use to reduced BP, thiazide plays a significant function in the prevention of osteoporosis and also fractures. Diuretic treatment could change nondippers to dippers as well as consequently provide an added therapeutic advantage of decreasing the danger of CV difficulties [52].

Combination therapy using Beta-blockers/diuretics in management of HTN:

The use of beta-blockers and diuretics is well-established in the management of HTN, and also their mix brings about an additive BP-lowering effect [53]. However, this specific mix has recently fallen out of favor as a result of a raised threat for new-onset diabetes. It has actually been shown that diuretics are connected with a 32% raised threat for new-onset diabetic issues compared to sugar pill or non-beta-blocker antihypertensive representatives; beta-blockers also have a 32% boosted danger compared with sugar pill or nondiuretic antihypertensive representatives [54]. This combination is as a result not suggested in patients with metabolic syndrome or prediabetes or that go to high danger for diabetes mellitus. In addition, both beta-blockers and also diuretics are understood to negatively impact erectile function [55]

Conclusion

Patients with hypertensive crises could call for immediate reduction in raised high blood pressure to stop and also detain modern end-organ damage. The best scientific setup in which to attain this blood pressure control remains in the intensive care unit, with making use of titratable intravenous hypotensive agents. Beta-blocker-based therapy, numerous possible randomized trials have recorded that diuretic-based treatment is efficient in reducing morbidity and also mortality in hypertensive patients. The advantages of diuretic therapy have actually been shown to be more significant in the senior compared to in younger patients. The result of diuretics is especially articulated when it comes to decrease of the risk of stroke and also somewhat less excellent with regard to the reduction of the danger of coronary heart disease.

References

1. **Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005):**Global burden of hypertension: analysis of worldwide data. Lancet, 365:217–223.
2. **Alcocer L, Cueto L (2008):** Hypertension, a health economics perspective. TherAdvCardiovasc Dis., 2: 147–155.
3. **Roger VL, Go AS, Lloyd-Jones DM*et al.*(2012):**American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation,125:e2–e220.
4. **Centers for Disease Control and Prevention (CDC) (2011):**Vital signs: prevalence, treatment, and control of hypertension – United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep., 60:103–108.
5. **Danaei G, Finucane MM, Lin JK et al. (2011)**:global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure) National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet, 377:568–577.
6. **Chobanian AV, Bakris GL, Black HR*et al.* (2003)**:for the National Heart, Lung, and Blood Institute. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42: 1206–1252.
7. **Tsolakas TC, Davies JP, Oram S (1964):**Propranolol in attempted maintenance of sinus rhythm after electrical defibrillation. Lancet, 2:1064.
8. **McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW (2009):**Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med., 150:784–794.
9. **Elliott WJ, Childers WK (2011):**Should B-blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities? CurrCardiol Rep., 13:507–516.
10. **MRC Working Party (1992):**Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J., 304:405–412.
11. **Prandin MG, Cicero AF, Veronesi M, Cosentino E, Dormi A, Strocchi E*et al.*(2007):**Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation. ClinExpHypertens., 29:553–562.
12. **Fagard R (2010):**Reappraisal of the European guidelines on hypertension management: the European Society of Hypertension Task Force document: a short review. Pol Arch Med Wewn., 120:31–35.
13. **Law MR, Morris JK, Wald NJ (2009):**Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ., 338:1665.
14. **Bangalore S, Sawhney S, Messerli FH. (2008):**Relation of beta-blocker—induced heart rate lowering and cardioprotection in hypertension. Journal of the American College of Cardiology, 52(18):1482–1489.
15. **Tomiyama H, Yamashina A (2010):**Non-invasive vascular function tests: their pathophysiological background and clinical application. Circulation Journal, 74(1):24–33.
16. **Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C (2010):**Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. European Heart Journal, 31:1865–1871.
17. **Jouven X, Empana J-P, Schwartz PJ, Desnos M, Courbon D, Ducimetière P(2005):**Heart-rate profile during exercise as a predictor of sudden death. The New England Journal of Medicine, 352:1951–1958.
18. **Tomiyama H, Hashimoto H, Tanaka H*et al.*(2010):**Synergistic relationship between changes in the pulse wave velocity and changes in the heart rate in middle-aged Japanese adults: a prospective study. Journal of Hypertension, 28:687–694.
19. **Prichard B, Gillam D (1978):** β-Adrenergic receptor blockade in hypertension, past, present and future. British Journal of Clinical Pharmacology, 5:379–399.
20. **Hjalmarson Å (2000):**Cardioprotection with beta-adrenoceptor blockers.Does lipophilicity matter? Basic Research in Cardiology, 95: 41–I45.

21. **Rinfret S, Abrahamowicz M, Tu J*et al.*(2007):**A population-based analysis of the class effect of β-blockers after myocardial infarction. American Heart Journal, 153:224–230.
22. **Carlberg B, Samuelsson O, Lindholm LH(2004):**Atenolol in hypertension: is it a wise choice? The Lancet, 364:1684–1689.
23. **De Caterina AR, Leone AM(2011):**The role of beta-blockers as first-line therapy in hypertension. Current Atherosclerosis Reports, 13:147–153.
24. **Dahlöf B, Sever PS, Poulter NR*et al.*(2005):**Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentrerandomised controlled trial. The Lancet, 366:895–906.
25. **Webb AJ, Fischer U, Mehta Z, Rothwell PM (2010):**Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. The Lancet, 375:906–915.
26. **Rothwell PM, Howard SC, Dolan E et al. (2010):** Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. The Lancet Neurology, 9:469–480.
27. **Neutel JM, Schnaper H, Cheung DG, Graettinger WF, Weber MA (1990):**Antihypertensive effects of β-blockers administered once daily: 24-hour measurements. American Heart Journal, 120:166–171.
28. **Morgan TO, Anderson A(2003):**Different drug classes have variable effects on blood pressure depending on the time of day. American Journal of Hypertension, 16:46–50.
29. **Sarafidis P, Bogojevic Z,Basta E, Kirstner E, Bakris GL(2008):**Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. The Journal of Clinical Hypertension 10:112–118.
30. **Neutel JM, Smith DHG, Ram CVS *et al.* (1993):**Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. The American Journal of Medicine, 94:181–187.
31. **Tomiyama H, Yamashina A(2010):**Non-invasive vascular function tests: their pathophysiological background and clinical application. Circulation Journal, 74:24–33.
32. **Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C (2010):**Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. European Heart Journal, 31:1865–1871.
33. **Dhakam Z, McEniery CM, Yasmin Y, Cockcroft JR, Brown MJ, Wilkinson IB (2006):**Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. American Journal of Hypertension, 19:214–219.
34. **Manisty CH, Hughes AD (2013):**Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. British Journal of Clinical Pharmacology, 75:79–92.
35. **FagardRH, Celis H, Thijs L, Wouters S(2009):**Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension, 54:1084–1091.
36. **Kampus P, Serg M, Kals J *et al.* (2011):**Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension, 57:1122–1128.
37. **GaponLI, Prilepova AA, Tsygol'nik MD(2005):**Effect of nebivolol on parameters of cerebral haemodynanics and 24-hour blood pressure profile in patients with arterial hypertension. Kardiologiya, 45:18–22.
38. **Fountoulaki K, Dimopoulos V, Giannakoulis J, Zintzaras E, Triposkiadis F(2005):**Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan. American Journal of Hypertension, 18:171–177.
39. **Psaty BM, Smith NL, Siscovick DS*et al.* (1997):** Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA, 277:739–745
40. **Beckett NS, Peters R, Fletcher AE et al. (2008):**Treatment of hypertension in patients 80 years of age or older. N Engl J Med., 358:1887–1898
41. **Brown MJ, Palmer CR, Castaigne A*et al.* (2000):**Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet ;356:366–372.
42. **ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002):**The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288:2981–2997.
43. **ALLHAT Collaborative Research Group (2000):** Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone,the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA ;283:1967–1975

44. **Einhorn PT, Davis BR, Massie BM et al. (2007):**The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J., 153:42–53.
45. **Wright JT, Probstfield JL, Cushman WC*et al.* (2009):**ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med., 169:832–842.
46. **Jamerson K, Weber MA, Bakris GL*et al.* (2008):**Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med., 359:2417–2428.
47. **SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. (1991):**final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 265:3255–3264.
48. **Messerli FH, Grossman E, Goldbourt U (1998):** Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA, 279:1903–1907
49. **Wing LM, Reid CM, Ryan P et al. (2003):**A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med., 348:583–592.
50. **Schoofs MW, van der Klift M, Hofman A*et al.* (2003):** Thiazide diuretics and the risk for hip fracture. Ann Intern Med., 139:476–482.
51. **Reid IR, Ames RW, Orr-Walker BJ et al. (2000):**Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med., 109:362–370.
52. **Uzu T, Kimura G (1999):**Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation, 100:1635–1638
53. **Lacourcière Y, Arnott W (1994):**Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens., 8:283–288.
54. **Messerli FH, Bangalore S, Julius S(2008):**Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation, 117: 2706–2715.
55. **Doumas M, Douma S(2006):**The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J ClinHypertens (Greenwich), 8:359–364.